TABLE 7.

Effect of MAPK inhibitors on MAPK activity in parental and acquired vemurafenib-resistant melanoma cell lines

Extracts of cells treated with non-toxic (<IC₁₀) concentration of each MAPK inhibitor or vehicle (control) for 1 h were examined for level of MAPK activation.

Inhibitor	MAPK activity relative to control
	A375	A375rVem	DM443	DM443rVem
AEMTa	0.17 ± 0.03	0.19 ± 0.05	0.15 ± 0.03	0.07 ± 0.01
TCS JNK60b	0.16 ± 0.01	0.11 ± 0.01	0.17 ± 0.04	0.1 ± 0.02
Skepinone-Lc	0.25 ± 0.01	0.30 ± 0.03	0.14 ± 0.02	0.08 ± 0.01

^a ERK inhibitor (15 μm).

^b JNK inhibitor (5.0 μm).

^c p38 inhibitor (1.0 μm).